Aurobindo Pharma's API Facility Receives Zero Observations in US FDA Inspection
Aurobindo Pharma said the US FDA inspection of its API manufacturing facility in Pydibhimavaram, Andhra Pradesh, concluded with zero observations.
Zero Observations | 15/09/2026 | By News Bureau
Granules India Unit V Facility Completes US FDA Inspection with Zero 483 Observations
Granules India Ltd. has announced that the company’s Unit V facility has completed the US Food and Drug Administration (FDA) inspection between April 8-12, 2024, resulting in zero 483 observations.
Zero Observations | 15/04/2024 | By Aishwarya | 1235
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy